Background and objective: Malignant pleurisy is associated with advanced oncological disease and dyspnoea is the most common presenting symptom. Pleurodesis is the preferred palliative and supportive treatment option, targeting symptom relief. The identification of clinical and endoscopic features that determine the success of talc pleurodesis in malignant pleurisy could guide clinical decision-making. Methods: All symptomatic patients with malignant pleurisy subjected to talc pleurodesis through medical thoracoscopy between January 2012 and December 2015 were included. Univariate and multivariate analyses were performed to identify factors associated with successful pleurodesis. Results: Of the 155 patients, 122 (78%) were classified as having a successful pleurodesis based on clinical and radiological criteria. Factors associated with unsuccessful pleurodesis (univariate analysis) were the presence of pleural adhesions (odds ratio (OR): 0.43 (95% CI: 0.19-0.96); P = 0.04), extensive spread of pleural lesions (OR: 0.17 (95% CI: 0.05-0.59); P = 0.001), the use of systemic corticosteroids (OR: 0.28 (95% CI: 0.10-0.83); P = 0.02) and a prolonged time period between the clinical diagnosis of the pleural effusion and the moment of pleurodesis (OR: 0.14 (95% CI: 0.06-0.32); P < 0.0001). The latter being associated with failure of pleurodesis in a multivariate analysis (OR: 0.08 (95% CI: 0.01-0.25); P < 0.0001). Chest ultrasound prior to pleurodesis showed a sensitivity of 91% and a specificity of 88% in predicting the success of pleurodesis. Conclusion: The success rate of pleurodesis in malignant pleurisy could potentially be enhanced by correct patient selection and early referral for pleurodesis. Ultrasonic assessment of pleural adhesions and potential lung expansion prior to pleurodesis is useful in clinical decision-making.
INTRODUCTION
Malignant pleurisy is associated with advanced oncological disease and a reduced life expectancy. [1] [2] [3] It is most frequently seen in lung cancer and breast cancer, accounting for 50-65% of all malignant effusions in published series. 1, 4, 5 Dyspnoea is the most common presenting symptom in patients with malignant pleurisy. [1] [2] [3] 5 Treatment options can be categorized as palliative and supportive, with emphasis on symptom control. 3, 5 Traditionally, thoracoscopy with pleurodesis is regarded as the preferred treatment option in patients with a relatively conserved performance status. 1, 3, 6 Sterile, ungraded talc is frequently used as a safe sclerosant during medical thoracoscopy. 1, 3, 7 More recently, the use of indwelling pleural catheters (IPC) has been shown to be successful 8 and cost-effective 9 as a treatment option for failed pleurodesis. 10 The identification of clinical features that are associated with the success of pleurodesis in malignant pleural effusions could potentially enhance the success rate and lead to a reduction in futile attempts of pleurodesis. Ultimately, these factors may guide clinical decision-making and guide the therapeutic choice between talc pleurodesis through medical thoracoscopy or the use of an IPC.
METHODS

Study design
We conducted a retrospective observational analysis of a prospectively recruited single-centre patient cohort.
SUMMARY AT A GLANCE
Identifying factors determining the success of talc pleurodesis in malignant pleurisy could guide clinical decision-making. This observational survey shows that a delay in referral of symptomatic patients for pleurodesis might compromise its success. Ultrasonic assessment of potential lung expansion can help to identify trapped lung.
All consecutive patients diagnosed with malignant pleuritis (confirmed by cyto-or histopathological diagnosis) and subjected to thoracoscopic talc pleurodesis between January 2012 and December 2015 were included in the survey.
Medical data concerning patient characteristics, primary tumour and treatment, pleural fluid characteristics, post-procedural radiological evolution, complications and survival were obtained from the medical files. Ultrasonic data prior to pleurodesis were only available for patients treated in 2015. These patient characteristics were grouped as either clinical parameters available before pleurodesis or real-time endoscopic findings. There was a mean follow-up period of 128 days.
This study was performed in accordance with the Declaration of Helsinki. This human study was approved by Ethics Committee Catholic University Leuven Belgium (approval: MP 02566). The study's clinical trial registration number is NCT0228865 registered with Clinicaltrials.gov.
Methodology
Successful pleurodesis was defined as a medical thoracoscopic intervention leading to symptomatic relief and radiological regression of the effusion without re-accumulation. Symptomatic relief was assessed by the reduction in self-reported dyspnoea at the first outpatient visit during the first month following pleurodesis. Radiological evaluation of a successful pleurodesis was based on the presence/absence of a residual pleural effusion on anteroposterior chest X-ray (CXR) of <20% of the initial pleural shadowing. CXR prior to pleurodesis, on days 1 and 4 and days 30-60 after pleurodesis were assessed depending on scheduled visits and patient survival. For the purpose of this study, complete lung expansion is defined as the absence of air or fluid in the pleural space on CXR. CXR were scored independently by two operators: one clinician being involved in the endoscopic procedures and one senior fellow involved only for the purpose of data registration, the latter being completely blinded for patient outcome. Whenever there was disagreement between both scorers, a consensus was made.
The presence or absence of pleural adhesions persisting after complete thoracoscopic drainage of the pleural effusion with partial collapse of the lung was taken into account. The extensiveness of pleural lesions was categorized upon the visual macroscopic evaluation during medical thoracoscopy. A case was classified as 'extensive' whenever more than one-third of the pleural surface was macroscopically invaded by tumour.
Between 1 January 2015 and 31 December 2015, chest ultrasound was consistently performed prior to pleurodesis to evaluate the potential expandability of the lung in 30 patients prior to pleurodesis as described by Salamonsen et al. 11 In sitting position, ultrasonic visualization of the atelectatic lung at the posterior base of the chest was performed and cine loops were acquired during breath hold at functional residual capacity for three or more cardiac cycles. In ultrasonic M-mode, the distance from top to trough of the undulating pleural line was measured in millimetre. The scoring of ultrasound clips is operator-dependent and was made by one and the same clinician for all subjects, noted in the patient's file prior to the procedure and therefore blinded for patient outcome. Based upon receiver-operating characteristics, the cut-off score for decreased lung expandability was set on a top-totrough distance of <2 mm.
Statistical analysis
Continuous data are expressed as means + SD in case of a normal distribution and as median values with interquartile range (IQR) in case of a skewed distribution. Nominal variables are expressed as percentages. To assess the distribution of variables, the D'AgostinoPearson omnibus normality test was used.
Statistical significance of continuous data was calculated by using the unpaired two-tailed t-test for normally distributed variables and the Mann-Whitney test for variables showing a skewed distribution. Contingency analysis of nominal data was performed using a two-sided Fisher exact test. Correlations were calculated using the Pearson rank coefficient.
Multivariate analysis was performed using a logistic regression model to determine predictive variables for the success of pleurodesis. The selection of variables in multivariate analysis was made based upon the results of the univariate analysis with forward selection. Odds ratios (OR) and 95% CI were calculated for the different parameters. Testing for collinearity was performed by calculating tolerance coefficients and variance inflation factors (VIF). Thresholds to detect significant collinearity were set at <0.2 for tolerance and >5.0 for VIF. The Box-Tidwell test was used to assess the interaction effect for continuous independent variables.
Actuarial survival rates were estimated with the Kaplan-Meier method and compared with the logrank test.
A significance level of <0.05 was considered statistically significant. Statistical calculations were performed using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA) and PASW 21 (SPSS, IBM, Chicago, IL, USA).
RESULTS
Epidemiology
Between January 2012 and December 2015, 172 consecutive patients with cytological or histological confirmation of malignant pleurisy were subjected to talc pleurodesis. In 17 of 172 (10%) patients, respiratory symptoms were absent and medical thoracoscopy was performed for diagnostic reasons with eventual pleurodesis based upon the macroscopic malignant appearance of the parietal pleura. These asymptomatic patients were excluded from data analysis. From the remaining 155 symptomatic patients, 121 subjects (78%) were categorized as resulting in a successful pleurodesis and 34 subjects were categorized as having an unsuccessful pleurodesis based on the before mentioned clinical and radiological criteria.
Median patient age was 67 years (IQR: 60-77), 55% were female patients. The origin of the primary tumour in our cohort was bronchopulmonary carcinoma (45%), mammary carcinoma (22%), ovarian cancer (10%), digestive carcinoma (9%), mesothelioma (6%) and other origin (8%).
Univariate analysis of patient characteristics
Data for age, gender, primary tumour, pleural lactate dehydrogenase (LDH), serum high-sensitive C-reactive protein (hs-CRP), macroscopic characteristic of pleural fluid, current treatment at the moment of pleurodesis (active systemic oncological treatment and systemic steroids) and interval between first thoracocentesis and pleurodesis as well as endoscopic findings such as the presence of pleural adhesions and the extensiveness of pleural lesions are summarized in Table 1 . Clinical patient characteristics associated with failure of pleurodesis were the use of systemic corticosteroids prior to pleurodesis and a prolonged time gap between the first thoracocentesis and pleurodesis. Macroscopic findings during thoracoscopy associated with failure of pleurodesis were the presence of pleural adhesions and the presence of extensive pleural disease. The presence of adhesions was increased in those patients with a prolonged (>38 days) interval between first thoracocentesis and pleurodesis (OR: 2.7 (95% CI: 1.2-5.9); P = 0.02).
Multivariate analysis of patient characteristics
Multivariate analysis was performed for clinical parameters only. A prolonged time interval between the first thoracocentesis and pleurodesis was associated with failed pleurodesis (Table 1) .
Overall survival
Median survival for those patients who were categorized as having a successful pleurodesis was 169 days as opposed to 66 days for those who had an unsuccessful procedure. There was a statistically significant difference in actuarial survival between both groups: a successful thoracoscopic talc pleurodesis was associated with a lower mortality (hazard ratio (HR): 0.52 (95% CI: 0.30-0.91); P = 0.02) (Fig. 1) .
Clinical and radiological evolution
In subjects classified as successful pleurodesis, a median of two thoracocenteses were performed (IQR: 1-3) prior to pleurodesis as opposed to three (IQR: 1-4) for failed subjects (P = 0.11). There is a good correlation between the number of thoracocentesis and the time interval between the first thoracocentesis and eventual pleurodesis (r = 0.5 (95% CI: 0.4-0.6); P < 0.0001).
Subjects were classified as unsuccessful pleurodesis based upon clinical criteria alone in 29%, based upon radiological criteria alone in 26% and based upon both clinical and radiological criteria in 45% of subjects. Among subjects classified as unsuccessful pleurodesis, the post hoc assessment of the cause for failure consisted of trapped lung in 15 subjects (43%), rapid disease progression in 8 subjects (24%), endobronchial obstruction unrevealed prior to pleurodesis in 5 subjects (15%), anasarca oedema and capillary leak syndrome in 2 subjects (6%), interfissural fluid reaccumulation (inhomogeneous talc poudrage) in 2 subjects (6%) and suboptimal positioning of the chest tube in 2 subjects (6%).
Radiological data on days 1 and 4 after pleurodesis and data on the median duration of chest tube drainage can be found in Table 2 . Lung expansion and presence of pleural fluid were evaluated by CXR on days 1 and 4.
Complications during the first 15 days after pleurodesis were rare and consisted of fever (3%), pneumonia (2%) and pleural infection (1%). Overall, procedurerelated complications were seen in nine patients (6%). In the group with successful pleurodesis, complications were seen in six patients (5%) as opposed to three patients in the group with failed pleurodesis (9%).
Chest ultrasound
The use of the M-mode was able to predict the incomplete expansion of the lung after pleurodesis with a sensitivity of 91% and a specificity of 88%. In this subgroup of patients, there was an excellent correlation between the top-to-trough distance measured in M-mode and the success rate of pleurodesis (r = 0.69 (95% CI: 0.44-0.84); P < 0.0001).
DISCUSSION
The current study shows that a prolonged time interval between the first thoracocentesis and the eventual pleurodesis is associated with a decrease in success rate of talc pleurodesis through medical thoracoscopy in symptomatic patients with malignant pleurisy. The use of chest ultrasound is an extension of the clinical assessment prior to the decision to perform pleurodesis.
The timing for referral for pleurodesis is an important clinical issue. In order to assess the time gap between the first clinical symptoms of a malignant pleurisy and the moment of pleurodesis, we included the time between the first thoracocentesis (for reasons of dyspnoea) and the moment of pleurodesis in our analysis. A prolonged time gap between a symptomatic pleurisy and pleurodesis was most strongly associated with the failure of pleurodesis. This could be explained by the formation of adhesions in the pleural cavity by recurrent thoracocentesis, the thickening of the visceral pleura over time and hence the increased risk of trapped lung. 3 As performance status potentially declines when dyspnoea persists as a result of pleural effusion and potentially impedes systemic oncological treatment, it is advisable to refer symptomatic patients with a clinical suspicion or a cytological confirmation of malignant pleurisy early for pleurodesis.
Chest ultrasound can detect the presence of pleural adhesions and is able to assess the potential for lung expansion. As described by Salamonsen et al., thoracic ultrasound with measurement of tissue movement and deformation of the atelectatic lobe (M-mode and/or elastography) prior to draining thoracocentesis can help identify a trapped lung. 11 Our survey using the M-mode alone corroborates these findings as we show a high sensitivity (91%) and specificity (88%) for decreased lung expandability after pleurodesis in a subset of patients. In case trapped lung is suspected prior the medical thoracoscopy, it is unlikely that pleurodesis will be able to prevent the reoccurrence of the effusion. In those subjects, the use of a tunnelled IPC could be a helpful alternative. Recent reports on the use of IPC show that IPC insertion is more than a treatment option in those patients in which pleurodesis is likely to fail or has failed. IPC is becoming a worthy alternative for pleurodesis in symptomatic malignant pleurisy as shown by the TIME2 randomized controlled trial (RCT) comparing IPC with chest tube and talc pleurodesis. 8 Although the primary end point in a 2017 RCT with superiority design was not met, 12 the use of IPC showed to be effective and led to fewer reinterventions and hospital admissions. The efficacy of IPC in inducing pleurodesis could potentially be enhanced by coating these devices with sclerosing agents such as silver nitrate. Results of the Seal-Mpe trial were published very recently showing safety and feasibility data on the potential use of such devices. 13 Whether daily IPC drainage could increase IPC treatment success compared with drainage guided by symptoms is currently under assessment in the multicentre randomized AMPLE-2 trial.
14 Because corticosteroids are known to interfere with pleurodesis [15] [16] [17] and the use of corticosteroids is frequent in malignant disease, the use of systemic corticosteroids from 48 h before until 24 h after pleurodesis was assessed. The doses varied between 4 and 64 mg methylprednisolone. Use of corticosteroids was only associated with failure of pleurodesis in the univariate analysis. After multivariate analysis, this association was not confirmed.
We observed that patients with successful pleurodesis were characterized by a longer overall survival, although this may not be interpreted as an indication for a survival benefit of talc pleurodesis in malignant pleurisy. In general, it makes sense to state that failed Column 1 shows the independent study variables classified as clinical characteristics or macroscopic findings during thoracoscopy. Column 2 shows the index value for discrimination between groups: median value as threshold for numeric variables and descriptor for categorical variables. Columns 3 and 4 show the proportional number per category for each variable for both the S-group and the F-group, respectively (dependent variables). OR for success over failure are reported in columns 5 and 6. Statistically significant results are shown in bold.
*−48 h till +24 h after pleurodesis. † Wald χ = 42.5 (P < 0.0001), Naegelkerke R 2 = 0.33. F-group, patients with failed pleurodesis; hs-CRP, high-sensitive C-reactive protein; LDH, lactate dehydrogenase; S-group, patients with successful pleurodesis. pleurodesis is a clinical marker for biological aggressive oncological disease and poor patient prognosis. In patients with a very limited life expectancy, omitting pleurodesis would be advisable. The reported radiological evolution after pleurodesis shows a proportion of complete lung expansion on day 4 of only 74% in the group considered to have undergone successful pleurodesis. This could be explained by the fact that the success of pleurodesis is defined not only by the radiographical image, but also by the patient-reported symptom relief. Overall, the radiological data on days 1 and 4 were very similar. From this, we concluded that the radiological image on day 1 seemed to be predictive of the outcome of pleurodesis. Furthermore, we noted that radiological appearance on CXR beyond 4 days of drainage only improved in a small group of patients, therefore concluding that systematic prolonged drainage more than 96 h, in order to obtain a delayed success of pleurodesis, does not seem useful as a general rule. Using this guidance, the overall duration of hospitalization could be shortened, potentially increasing the cost-effectiveness of pleurodesis for malignant pleurisy.
The current study is limited by its retrospective design and the lack of a validation series. In only a subset of subjects, ultrasonic assessment prior to pleurodesis was performed according to the findings of the 2014 paper by Salamonsen et al.
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In conclusion, the current survey endorses the early referral for talc pleurodesis in symptomatic patients with malignant pleurisy and the use of thoracic ultrasound prior to the procedure, as both potentially enhance the success rate of pleurodesis through medical thoracoscopy. 
